safeti
test
modifi
vaccinia
viru
ankara
mva
licens
thirdgener
vaccin
smallpox
serv
potent
vector
system
develop
new
candid
vaccin
infecti
diseas
cancer
histor
mva
develop
serial
tissu
cultur
passag
primari
chicken
cell
vaccinia
viru
strain
ankara
clinic
use
avoid
undesir
side
effect
convent
smallpox
vaccin
adapt
growth
avian
cell
mva
lost
abil
replic
mammalian
host
lack
mani
gene
orthopoxvirus
use
conquer
advanc
viru
research
volum
elsevi
inc
host
cell
environ
biolog
wellcharacter
mutant
viru
mva
facilit
fundament
research
elucid
function
poxviru
hostinteract
factor
extrem
safe
viral
vector
mva
vaccin
found
immunogen
protect
variou
preclin
infect
model
multipl
recombin
mva
current
undergo
clinic
test
vaccin
human
immunodefici
virus
mycobacterium
tuberculosi
plasmodium
falciparum
versatil
mva
vector
vaccin
platform
readili
demonstr
swift
develop
experiment
vaccin
immun
emerg
infect
middl
east
respiratori
syndrom
recent
advanc
includ
promis
result
clinic
test
recombin
mvaproduc
antigen
highli
pathogen
avian
influenza
viru
ebola
viru
review
summar
current
knowledg
mva
uniqu
strain
vaccinia
viru
discuss
prospect
exploit
viru
research
tool
poxviru
biolog
safe
viral
vector
vaccin
challeng
exist
futur
bottleneck
vaccinolog
poxvirus
engin
express
foreign
gene
product
establish
tool
develop
novel
vaccin
therapeut
biomed
research
larg
packag
capac
heterolog
dna
strict
virusspecif
control
recombin
gene
express
lack
viru
persist
host
immunogen
efficaci
vaccin
eas
vector
vaccin
product
import
contributor
success
stori
concern
safeti
convent
vaccinia
virus
smallpox
vaccin
address
studi
replic
defect
virus
unabl
produc
infecti
progeni
human
cell
today
highli
attenu
vaccinia
viru
strain
mva
consid
one
vaccin
virus
choic
preclin
clinic
research
mva
replicationdefici
cell
mammalian
origin
fail
produc
mani
virul
factor
encod
convent
vaccinia
viru
safeti
gener
environ
mva
handl
condit
biosafeti
level
nonrepl
mva
enter
target
cell
activ
molecular
life
cycl
express
class
viral
recombin
gene
therefor
recombin
mva
establish
extrem
safe
effici
viral
vector
system
basic
research
develop
vaccin
suitabl
industri
scale
product
review
develop
mva
product
serial
tissu
cultur
passag
chicken
embryo
fibroblast
cef
key
biolog
properti
recent
accomplish
vaccin
research
use
recombin
mva
modifi
vaccinia
viru
ankara
mva
develop
serial
passag
chicken
fibroblast
tissu
cultur
serv
safer
vaccin
last
year
smallpox
erad
campaign
ancestor
viru
vaccinia
viru
strain
ankara
origin
propag
skin
calv
donkey
turkish
vaccin
institut
ankara
smallpox
vaccin
product
vaccinia
viru
strain
ankara
brought
munich
ad
strain
collect
institut
infecti
diseas
tropic
medicin
univers
munich
herrlich
mayr
cultiv
viru
chorioallantoi
membran
cam
embryon
chicken
egg
therefor
name
chorioallantoi
vaccinia
viru
ankara
cva
herrlich
mayr
bayerisch
landesimpfanstalt
unchen
bavarian
state
institut
vaccin
cva
grown
skin
calv
manufactur
smallpox
vaccin
vaccin
campaign
munich
munich
addit
univers
munich
cva
test
passag
experi
variou
tissu
cultur
studi
genet
stabil
evolut
orthopoxvirus
mayr
munz
report
passag
cva
primari
cef
result
develop
infect
phenotyp
restrict
host
cell
tropism
discuss
similar
biolog
properti
known
poxvirus
highli
adapt
specif
host
eg
variola
viru
varv
human
fowlpox
viru
chicken
success
passag
vaccinia
viru
minc
chicken
embryo
tissu
describ
success
strategi
vitro
amplif
smallpox
vaccin
viru
cultur
system
ward
serial
passag
cva
cef
continu
anton
mayr
colleagu
passag
cef
viru
renam
modifiziert
vakziniaviru
ankara
mva
provid
bavarian
state
institut
vaccin
test
suitabl
smallpox
vaccin
product
stickl
hochsteinmintzel
phenotyp
chang
relat
repeat
passag
cva
viru
cef
cultur
first
observ
upon
infect
embryon
egg
mani
year
cam
inocul
goldstandard
experiment
system
phenotyp
studi
variou
poxvirus
goodpastur
et
al
goodpastur
et
al
mayr
et
al
mva
infect
character
format
small
prolif
lesion
cam
contrast
consider
larger
cam
lesion
variabl
size
area
central
necrosi
typic
found
cva
convent
vaccinia
virus
herrlich
mayr
interestingli
cam
lesion
mva
note
close
resembl
induc
variola
fowlpox
virus
follow
egg
inocul
mayr
munz
stickl
hochsteinmintzel
addit
observ
earli
mva
lost
capac
vaccinia
viru
caus
promin
cytopath
effect
form
plaqu
firstgener
tissu
cultur
cef
primari
bovin
porcin
kidney
cell
human
hela
cell
mayr
munz
characterist
chang
vivo
behavior
viru
report
experiment
inocul
rabbit
german
great
white
mayr
et
al
stickl
hochsteinmintzel
intraderm
infect
cutan
infect
scarif
convent
vaccinia
viru
vacv
result
format
typic
skin
lesion
lesion
total
absent
follow
inocul
mva
suggest
substanti
loss
virul
upon
vivo
infect
data
confirm
find
newborn
strain
nmri
day
old
adult
mice
g
surviv
intracerebr
inocul
mva
dose
result
mortal
follow
cva
infect
mayr
et
al
stickl
hochsteinmintzel
inabl
mva
induc
primari
reaction
pock
lesion
form
upon
intraderm
cutan
inocul
also
confirm
cynomolgu
monkey
model
macacu
fasciculari
macaqu
toler
intracrani
inocul
mva
without
obviou
advers
effect
wherea
anim
inject
cva
develop
sever
system
diseas
moreov
intraderm
intramuscular
vaccin
infecti
unit
iu
mva
vaccin
protect
macaqu
sever
diseas
follow
intraven
challeng
varv
strain
madra
mayr
et
al
stickl
hochsteinmintzel
data
earli
preclin
character
laboratori
anim
alreadi
suggest
mva
maintain
immunogen
vaccin
demonstr
dramat
loss
virul
upon
cef
passag
viru
renam
mva
transfer
bavarian
state
vaccin
institut
munich
evalu
safer
smallpox
vaccin
clinic
trial
first
mva
vaccin
prepar
test
human
produc
cef
cultur
contain
iu
mvaml
stickl
hochsteinmintzel
first
attempt
use
vaccin
scarif
fail
induc
kind
skin
reaction
applic
intracutan
inocul
ml
vaccin
suspens
contain
iu
mva
chosen
first
clinic
test
primari
vaccin
individu
age
year
stickl
hochsteinmintzel
day
minor
local
reaction
develop
site
inject
red
swell
skin
forearm
howev
investig
observ
pock
lesion
symptom
normal
associ
smallpox
vaccin
none
individu
develop
fever
bodi
temperatur
interestingli
note
mva
applic
fail
induc
circul
antibodi
inhibit
hemagglutin
vacv
thu
efficaci
immun
test
secondari
vaccin
scarif
use
vacv
strain
elstre
individu
receiv
mva
primari
vaccin
skin
reaction
typic
followup
smallpox
vaccin
note
patient
suggest
success
primari
immun
mva
vaccin
data
support
clinic
develop
mva
smallpox
vaccin
follow
test
patient
stickl
et
al
bavarian
state
vaccin
institut
munich
obtain
first
market
author
mva
primari
prevaccin
smallpox
germani
paulehrlichinstitut
mva
smallpox
vaccin
given
human
without
document
sever
advers
event
otherwis
associ
use
convent
vacv
vaccin
mahnel
mayr
immun
first
licens
mva
vaccin
stop
end
smallpox
vaccin
program
germani
year
later
target
genet
modif
vaccinia
viru
genom
becam
possibl
concept
gener
recombin
virus
gene
express
vaccin
also
restor
interest
mva
restrict
map
mva
genom
base
clonal
viru
isol
cef
passag
mva
reveal
alter
mva
genom
like
genet
basi
attenu
growth
restrict
meyer
et
al
comparison
genom
map
cva
ancestor
virus
reveal
mva
genom
harbor
larg
delet
mutat
affect
mani
gene
function
virushost
interact
fig
first
import
observ
includ
failur
rescu
product
mva
growth
cell
human
origin
restor
vacv
host
rang
gene
despit
presenc
second
vacv
host
rang
gene
mva
genom
ii
absenc
gene
major
vacv
atyp
inclus
bodi
protein
lack
protein
among
polypeptid
made
mvainfect
cell
iii
demonstr
code
sequenc
vacv
hemagglutinin
ha
start
right
adjac
delet
iii
within
mva
genom
year
later
allow
identifi
truncat
ha
promot
sequenc
explain
haneg
phenotyp
mva
inabl
detect
haspecif
antibodi
upon
mva
immun
antoin
et
al
notabl
earli
find
complement
elucid
fulllength
sequenc
mva
genom
antoin
et
al
discoveri
mva
lack
import
immunomodulatori
gene
highli
attenu
phenotyp
viru
also
encourag
evalu
mva
express
vector
yet
mva
product
replic
cell
mammalian
origin
highlevel
express
recombin
gene
doubt
host
rang
mutant
vacv
inhibit
alreadi
earli
life
cycl
drillien
et
al
drillien
et
al
code
sequenc
escherichia
coli
enzym
guaninephosphoribosyltransferas
serv
first
heterolog
gene
insert
express
site
delet
iii
mva
genom
sutter
moss
surprisingli
product
earli
late
viral
protein
turn
unimpair
mvainfect
human
cell
fig
inde
uniqu
abil
effici
express
viral
recombin
gene
support
gener
applic
except
safe
viral
vector
ascertain
whether
mva
vector
would
applic
immun
experi
recombin
antigen
first
mva
vector
vaccin
construct
test
simultan
express
ha
nucleoprotein
np
gene
influenza
viru
sutter
et
al
recombin
mva
found
immunogen
sinc
vaccin
mice
variou
rout
result
high
level
serum
antibodi
inhibit
hemagglutin
influenza
viru
moreov
vector
vaccin
also
elicit
strong
cytotox
cell
respons
direct
influenza
viru
protein
importantli
anim
could
complet
protect
lethal
respiratori
tract
influenza
challeng
follow
singl
inocul
rel
low
dose
recombin
mva
vaccin
gener
first
mva
vector
foreign
gene
sequenc
target
precis
site
natur
exist
delet
iii
mva
genom
strategi
design
vector
avoid
unnecessari
chang
genotyp
phenotyp
result
recombin
mva
develop
recombin
mva
vaccin
heterolog
gene
simian
immunodefici
viru
siv
parainfluenza
viru
insert
delet
iii
rapidli
follow
hirsch
et
al
wyatt
et
al
also
natur
delet
ii
within
mva
genom
success
use
insert
site
express
recombin
bacteriophag
rna
polymeras
sutter
et
al
addit
thymidin
kinas
locu
wellexploit
insert
site
replicationcompet
vacv
vector
likewis
serv
gener
recombin
mva
deliv
antigen
plasmodium
berghei
schneider
et
al
poxvirus
includ
prototyp
orthopoxviru
vacv
excel
model
studi
virushost
interact
vacv
effici
antagon
activ
interferon
ifn
cytokin
chemokin
innat
immun
signal
review
see
smith
et
al
herebi
vacv
exploit
express
solublebind
protein
receptor
antagonist
viral
immun
evas
protein
work
intracellularli
inhibit
apoptosi
interfer
host
signal
pathway
activ
antivir
immun
mechan
notabl
mani
vacv
gene
involv
immun
evas
inactiv
truncat
mva
genom
antoin
et
al
interestingli
earli
studi
mayr
cowork
suggest
distinct
immun
stimulatori
activ
associ
experiment
mva
inocul
mayr
et
al
eg
intraperiton
applic
viru
mice
enhanc
vivo
clearanc
carbon
marker
particl
blood
anim
suggest
increas
phagocyt
activ
immun
cell
day
mva
inocul
addit
intranas
deliveri
mva
rabbit
result
within
hour
induct
serum
interferon
effici
inhibit
sindbi
viru
replic
vitro
infect
assay
recent
past
variou
studi
elucid
mechan
mvamedi
induct
type
ifn
follow
vitro
vivo
infect
dai
et
al
delaloy
et
al
ishii
et
al
waibler
et
al
waibler
et
al
inde
lack
mani
immun
evas
factor
failur
mva
infect
interfer
earli
key
host
cell
defenc
mechan
may
explain
sever
growth
restrict
mva
high
attenu
upon
vivo
infect
immunogen
use
vaccin
moreov
due
extens
loss
genet
inform
mva
may
serv
particularli
use
tool
studi
vacv
hostregulatori
gene
obvious
sever
pathway
host
cell
defenc
target
multipl
vacv
protein
phenotyp
vacv
singl
gene
mutant
may
mask
complementari
function
viral
gene
dobson
tschark
three
obviou
strategi
use
mva
elucid
function
select
vacv
hostinteract
factor
remain
regulatori
gene
mva
genom
target
inactiv
ii
candid
vacv
gene
miss
mva
reinsert
genom
rescu
hostinteract
phenotyp
iii
combin
latter
approach
may
serv
investig
put
complementari
gene
function
follow
describ
principl
learnt
mva
research
may
help
better
understand
regul
virushost
interact
like
influenc
safeti
immunogen
vacvbas
vaccin
therapeut
fig
one
strike
featur
mva
inabl
replic
cell
mammalian
origin
carrol
moss
drexler
et
al
meyer
et
al
contrast
wildtyp
vacv
broad
cellular
host
rang
product
infect
variou
cell
substrat
drillien
et
al
noteworthi
poxviru
infect
reli
avail
specif
cellular
receptor
virus
effici
bind
enter
mani
differ
cell
divers
anim
speci
entri
howev
success
vacv
replic
depend
function
activ
subset
viral
gene
socal
host
rang
gene
review
see
bratk
et
al
haller
et
al
mcfadden
viral
gene
encod
regulatori
protein
control
intracellular
host
defenc
eg
manipul
sens
viral
pathogen
associ
molecular
pattern
signal
transduct
cell
cycl
onset
program
cell
death
emin
viral
regul
intracellular
host
tropism
still
function
mva
genom
includ
protein
follow
nomenclatur
establish
genom
vacv
strain
copenhagen
goebel
et
al
vacv
gene
encod
vacv
protein
known
control
viru
replic
mammalian
cell
gene
function
need
inactiv
restrict
growth
wildtyp
vacv
gillard
et
al
perku
et
al
alreadi
earli
work
drillien
cowork
suggest
replic
defect
vacv
host
rang
mutant
absenc
establish
level
viral
gene
express
drillien
et
al
howev
sever
growth
defect
highli
attenu
mva
rescu
genom
engin
contain
function
copi
suggest
addit
viral
factor
await
discoveri
back
et
al
meyer
et
al
sutter
et
al
howev
mva
lack
late
gene
express
human
murin
cell
induc
phosphoryl
eukaryot
translat
initi
factor
defici
late
gene
express
phosphoryl
absenc
prevent
shown
reinsert
gene
genom
mva
back
et
al
complementari
function
intrigu
two
gene
encod
protein
unrel
sequenc
interestingli
recent
studi
identifi
human
gene
steril
alpha
motif
domaincontain
tryptophanaspart
acid
repeat
host
restrict
factor
poxvirus
target
liu
mcfadden
sivan
et
al
date
rather
littl
known
molecular
function
assum
act
innat
antivir
defens
pathway
await
elucid
viral
protein
encod
gene
wellknown
intracellular
inhibitor
ifninduc
antivir
activ
host
cell
chang
et
al
davi
et
al
homolog
alpha
subunit
serv
pseudosubstr
doublestrand
rna
dsrna
activ
protein
kinas
pkr
prevent
virusinduc
phosphoryl
pkr
turn
sequest
dsrna
inhibit
stimul
pkr
prevent
activ
oligoadenyl
synthas
endoribonucleas
rnasel
addit
describ
independ
inhibit
phosphoryl
transcript
factor
thu
block
product
type
ifn
xiang
et
al
ifn
evas
mechan
provid
substanti
contribut
broad
cellular
host
rang
vacv
numer
host
rang
phenotyp
vacv
mutant
lack
gene
found
werden
et
al
interestingli
cefadapt
mva
maintain
fulli
activ
sequenc
inde
function
gene
requir
mva
replic
cef
function
inhibitor
apoptosi
andor
ifn
induct
allow
unimpair
late
protein
synthesi
hornemann
et
al
human
hela
hacat
cell
studi
mva
mutant
reveal
also
essenti
secur
viral
intermedi
late
protein
synthesi
counteract
host
cellspecif
activ
level
antivir
pathway
pkr
rnasel
also
increas
type
ifn
andor
chemokin
product
compar
wildtyp
mva
infect
primari
murin
fibroblast
murin
bone
marrowderiv
dendrit
cell
agreement
known
activ
transcript
factor
absenc
dai
et
al
ishii
et
al
likewis
apoptosi
induct
infect
murin
fibroblast
requir
proapoptot
cellular
protein
noxa
well
line
activ
noxa
delaloy
et
al
fischer
et
al
cell
death
apoptosi
import
defenc
mechan
protect
host
viral
infect
turn
poxvirus
evolv
specif
viral
protein
inhibit
onset
program
cell
death
regulatori
protein
relev
determin
viru
tropism
cellular
level
taylor
barri
vacv
protein
encod
gene
antiapoptot
protein
structur
propos
block
apoptosi
bind
proapoptot
famili
protein
bak
postigo
et
al
wasilenko
et
al
wasilenko
et
al
also
conserv
mva
genom
mva
induc
enhanc
apoptosi
hela
cell
mous
embryon
fibroblast
fischer
et
al
addit
work
demonstr
trigger
apoptosi
predominantli
requir
induct
proapoptot
protein
noxa
activ
proapoptot
bak
ferrer
et
al
herebi
activ
noxa
link
recognit
viral
rna
upregul
type
ifn
signal
thu
noxadepend
induct
apoptosi
observ
upon
infect
fischer
et
al
may
explain
failur
sequest
viral
rna
absenc
result
strong
activ
proapoptot
noxa
fig
ankyrin
repeat
ank
motif
found
mani
poxviru
regulatori
protein
determin
cellular
host
tropism
andor
counteract
antivir
host
respons
control
nfkb
signal
herbert
et
al
otherwis
ank
motif
describ
import
mani
proteinprotein
interact
cellular
ank
protein
involv
divers
regulatori
task
includ
cellular
transcript
cell
cycl
control
cellular
differenti
mosavi
et
al
ankcontain
protein
encod
mva
genom
ankyrinlik
protein
homologu
vacv
cop
gene
product
addit
ank
contain
fboxlik
pranc
pox
protein
repeat
ankyrin
ctermin
domain
mercer
et
al
mva
bind
cellular
form
scf
ubiquitin
ligas
complex
fboxdepend
manner
sperl
et
al
mva
mutant
show
reduc
transcript
intermedi
late
viral
gene
suffer
drastic
impair
late
protein
synthesi
human
murin
cell
sperl
et
al
thu
essenti
complet
mva
molecular
life
cycl
interestingli
fbox
domain
dispens
rescu
mutant
phenotyp
suggest
multipl
activ
hostregulatori
mva
protein
mva
intens
use
vector
vaccin
test
varieti
infecti
diseas
see
section
cancer
howev
still
know
littl
influenc
mva
vaccin
immunogen
vaccin
efficaci
regard
mva
protein
regul
host
cell
tropism
inde
modul
function
activ
protein
could
result
quit
differ
outcom
one
scenario
inactiv
regul
may
enhanc
mvamedi
activ
innat
immun
system
may
lead
improv
protect
immun
anoth
possibl
scenario
reduc
mva
vaccin
efficaci
fig
role
mva
regulatori
protein
within
intracellular
viru
life
cycl
effici
sequest
dsrna
produc
infect
counteract
activ
antivir
host
enzym
oa
oligoadenyl
synthetas
rnasel
ribonucleas
l
pkr
protein
kinas
rnaactiv
addit
function
protein
prevent
activ
host
proapoptot
protein
noxa
block
phosphoryl
transcript
factor
inhibit
product
type
interferon
mva
protein
bind
prevent
activ
proapoptot
host
protein
baxbak
noxa
act
effici
inhibitor
cytochrom
c
releas
cyto
c
apoptosi
induct
level
host
cell
mitochondria
delet
gene
eg
may
drastic
impair
viral
replic
level
gene
express
mvamedi
antigen
synthesi
addit
regulatori
gene
target
host
tropism
mva
genom
also
contain
number
gene
known
immunomodulatori
function
one
interest
exampl
gene
encod
vacv
receptor
protein
viral
cytokinebind
protein
highspecif
affin
alcami
smith
sprigg
et
al
thought
play
import
role
regul
inflammatori
respons
follow
vacv
infect
smith
synthesi
could
demonstr
variou
mvainfect
cultur
cell
zimmerl
et
al
interestingli
primari
murin
myeloid
dendrit
cell
import
produc
cell
upon
mva
infect
free
detect
absenc
use
delet
mutant
immun
mva
delet
mutant
led
significantli
enhanc
virusspecif
tcell
respons
increas
protect
capac
lethal
challeng
infect
virul
vacv
strain
western
reserv
wr
addit
gene
sequenc
encod
vacv
bind
protein
gene
also
function
retain
mva
genom
vacv
bind
solubl
prevent
reach
cellular
receptor
target
proinflammatori
antivir
function
cytokin
born
et
al
calderara
et
al
symon
et
al
possibl
enhanc
vaccin
immunogen
inactiv
gene
mva
investig
two
previou
vaccin
studi
mice
cottingham
cowork
found
signific
differ
vacvspecif
cell
respons
compar
vaccin
base
mva
mutat
wildtyp
mva
cottingham
et
al
second
studi
demonstr
function
activ
mva
immun
mva
delet
mutant
increas
vacv
epitopespecif
tcell
respons
protect
capac
vacv
challeng
infect
faliven
et
al
diminish
inflammatori
host
respons
anoth
strategi
vacv
product
secret
viral
chemokin
receptor
protein
prevent
chemokinemedi
recruit
leukocyt
fig
et
al
graham
et
al
ng
et
al
interestingli
mva
lost
much
vacv
immun
evas
activ
mva
effici
induc
chemotaxi
trigger
rapid
immigr
leukocyt
site
vivo
inocul
lehmann
et
al
yet
mva
still
produc
secret
protein
bind
chemokin
rel
low
affin
suggest
anoth
function
mechan
block
bind
chemokin
cellular
receptor
bahar
et
al
moreov
delet
gene
mva
improv
tcell
immunogen
protect
capac
vaccin
vacv
encod
impress
varieti
intracellular
viru
protein
inhibit
host
signal
pathway
nfkb
review
see
smith
et
al
togeth
protein
serv
dampen
innat
host
respons
block
induct
type
ifn
chemokin
proinflammatori
cytokin
mva
fail
function
produc
substanti
number
inhibitori
protein
includ
inde
mva
infect
induc
activ
nfkb
oie
pickup
reinsert
origin
vacv
gene
sequenc
mva
genom
allow
elucid
function
nfkb
inhibitor
hinthong
et
al
shisler
jin
inhibitori
gene
fulli
conserv
mva
interestingli
remov
mva
genom
report
contribut
higher
frequenc
antigenspecif
cell
enhanc
polyfunction
cell
higher
antigenspecif
antibodi
titer
test
recombin
mvaproduc
hiv
candid
antigen
garber
et
al
et
al
similar
improv
immunogen
also
describ
recombin
mvahiv
viru
delet
gene
et
al
data
suggest
function
activ
mva
despit
fact
mva
gene
harbor
infram
delet
caus
loss
five
amino
acid
aa
vacv
interest
regulatori
protein
act
inhibitor
activ
within
nucleu
infect
cell
fig
shortli
erad
smallpox
vacv
acquir
new
mission
eukaryot
clone
vector
express
heterolog
gene
homolog
recombin
frequent
occur
vacv
genom
within
infect
cell
discov
allow
effici
insert
foreign
dna
vacv
genom
mackett
et
al
panicali
paoletti
technolog
enabl
develop
new
recombin
vaccin
could
benefici
decreas
impact
variou
infecti
diseas
year
replicationcompet
recombin
vacv
success
introduc
use
veterinari
medicin
accomplish
recombin
vacv
vaccin
rabi
blancou
et
al
esposito
et
al
kieni
et
al
applic
recombin
vacv
vaccin
human
lag
behind
restrict
due
wellknown
side
effect
vacv
smallpox
vaccin
circumst
avail
replicationdefici
vacv
nyvac
mva
spur
establish
except
safe
nextgener
poxvir
vector
sutter
moss
tartaglia
technolog
recombin
mva
adapt
vacv
still
frequent
effect
practic
strategi
gener
recombin
poxvirus
employ
homolog
dna
recombin
infect
cell
rel
frequent
event
vacv
genom
replic
mackett
et
al
nakano
et
al
recombin
typic
direct
gene
transfer
plasmid
transcript
control
foreign
gene
variou
virusspecif
promot
use
achiev
moder
strong
express
whole
viru
replic
cycl
baldick
et
al
chakrabarti
et
al
davison
moss
di
pilato
et
al
wennier
et
al
wyatt
et
al
usual
plasmid
carri
specif
express
unit
virusspecif
promot
next
multipl
clone
site
insert
variou
foreign
gene
sequenc
select
marker
facilit
clonal
isol
recombin
mva
mackett
et
al
staib
et
al
foreign
gene
sequenc
marker
gene
flank
side
genom
mva
sequenc
direct
recombin
express
cassett
favor
loci
nonessenti
region
mva
genom
mva
site
major
delet
suit
insert
foreign
gene
sequenc
without
affect
essenti
region
mva
genom
sutter
moss
sutter
et
al
today
delet
site
iii
serv
one
frequent
use
insert
loci
song
et
al
volz
et
al
addit
standard
insert
site
use
convent
vacv
thymidin
kinas
gene
locu
ha
gene
locu
readili
establish
construct
recombin
mva
antoin
et
al
schneider
et
al
moreov
due
high
fidel
homolog
recombin
also
small
nonessenti
region
mva
gene
use
introduc
heterolog
dna
vector
construct
wyatt
et
al
multipl
insert
site
may
allow
integr
variou
express
unit
foreign
gene
mva
genom
opt
multival
recombin
vaccin
gener
recombin
mva
cell
infect
mva
simultan
transfect
respect
mva
transfer
plasmid
allow
homolog
recombin
kremer
et
al
staib
et
al
recombin
mva
virus
clonal
isol
repetit
cell
cultur
passag
screen
specif
select
marker
differ
protocol
establish
allow
differenti
wildtyp
recombin
mva
first
approach
took
advantag
specif
enzym
allow
color
discrimin
transfer
vector
contain
antibiot
select
marker
report
gene
allow
screen
due
chang
phenotyp
coexpress
e
coli
carrol
moss
chakrabarti
et
al
among
coexpress
antibiot
resist
marker
e
coli
gpt
gene
encod
enzym
xanthineguaninephosphoribosyltransferas
frequent
use
purif
recombin
virus
domin
posit
select
resist
mycophenol
acid
falkner
moss
isaac
et
al
stain
procedur
requir
addit
time
tissu
cultur
supplement
agar
overlay
use
chromogen
substrat
antibiot
complement
defect
viru
product
faster
conveni
method
obtain
recombin
mva
virus
first
growth
select
protocol
initi
use
vacv
host
rang
gene
rescu
recombin
mva
replic
rabbit
kidney
cell
staib
et
al
blasco
moss
introduc
select
vacv
plaqu
format
coinsert
gene
adapt
isol
mva
vector
virus
blasco
moss
blasco
moreov
mva
mutant
viru
match
complement
cell
line
enabl
growth
select
base
essenti
gene
function
ricci
et
al
gener
recombin
mva
virus
base
wellestablish
techniqu
isol
clonal
virus
includ
use
serumfre
media
markerfre
recombin
virus
specif
regulatori
guidelin
help
supervis
gener
recombin
vector
vaccin
suitabl
applic
human
ema
yet
consequ
gener
recombin
mva
certain
extent
limit
use
prefer
method
kremer
et
al
eg
one
prefer
scheme
isol
recombin
mva
screen
transient
cosynthesi
marker
protein
without
enzym
activ
relat
antibiot
chemotherapeut
resist
phenotyp
fluoresc
protein
green
red
fluoresc
protein
conveni
use
wellcharacter
inert
marker
protein
altern
procedur
engin
poxviru
genom
pioneer
recent
entir
vacv
mva
genom
clone
bacteri
artifici
chromosom
bac
engin
e
coli
homolog
recombin
bacteriophag
lambdaderiv
enzym
cottingham
et
al
moss
modifi
bac
clone
use
produc
pure
recombin
poxviru
mammalian
cell
initi
assist
helper
viru
without
requir
plaqu
purif
anoth
uptod
method
yet
adapt
construct
recombin
mva
util
system
insert
altern
gene
sequenc
vacv
genom
yuan
et
al
importantli
independ
methodolog
use
gener
recombin
mva
viru
new
vector
viru
thoroughli
qualiti
control
genet
ident
puriti
genet
stabil
recombin
gene
express
growth
characterist
kremer
et
al
typic
vitro
character
alreadi
start
process
clonal
isol
mva
vector
virus
plaqu
purif
collect
straightforward
methodolog
establish
confirm
genom
ident
correct
insert
target
gene
sequenc
within
mva
genom
use
fingerprint
pcr
assess
insert
site
six
natur
occur
delet
site
level
kinet
recombin
protein
synthesi
stabil
posttransl
modif
foreign
target
protein
typic
monitor
use
standard
vitro
infect
experi
antigenspecif
immun
detect
assay
eg
western
blot
context
also
import
analyz
growth
capac
recombin
mva
wellknown
replic
defici
mva
mammalian
cell
key
biolog
characterist
mva
allow
genet
modifi
viru
handl
germani
condit
minim
potenti
biohazard
laboratori
personnel
clinician
patient
gener
environ
bundesamt
ur
vebraucherschutz
und
lebensmittelsicherheit
therefor
new
recombin
mva
routin
test
growth
characterist
cell
human
origin
prefer
cell
normal
differenti
hacat
cell
boukamp
et
al
jordan
et
al
lohr
et
al
moreov
encourag
design
cell
line
alreadi
use
manufactur
first
candid
vaccin
approv
clinic
evalu
genzel
medic
research
develop
ongo
effort
focu
studi
candid
vaccin
infecti
diseas
complic
prevent
eg
caus
newli
emerg
pathogen
sever
acut
respiratori
syndrom
coronaviru
west
nile
viru
wnv
avian
influenza
viru
decad
avail
safe
effici
vaccin
differ
influenza
virus
one
biggest
demand
public
health
system
today
infect
season
influenza
viru
kill
peopl
everi
year
main
risk
group
compris
elderli
immunocompromis
children
highest
incid
fatal
outcom
loubet
et
al
moreov
addit
circul
season
influenza
virus
continu
threat
new
pandem
influenza
virus
might
aris
pig
bird
herfst
et
al
last
centuri
four
pandem
togeth
caus
million
death
russel
et
al
henc
surpris
influenza
target
first
recombin
mva
vaccin
vector
viru
design
codeliv
influenza
viru
antigen
ha
np
mvahanp
sutter
et
al
balbc
mice
immun
mvahanp
mount
effici
level
haspecif
antibodi
well
haand
npspecif
cell
singl
intramuscular
immun
suffici
protect
mice
lethal
respiratori
challeng
influenza
viru
subsequ
mvahanp
shown
induc
mucos
immun
follow
oral
immun
allow
partial
protect
heterolog
influenza
viru
subtyp
challeng
infect
bender
et
al
result
test
first
recombin
mvaexpress
influenza
viru
antigen
took
sometim
encourag
multitud
experi
target
influenza
veterinari
well
human
medicin
breathnach
cowork
character
recombin
mvaproduc
ha
np
equin
influenza
viru
vaccin
poni
mvaha
induc
robust
level
antibodi
protect
challeng
influenza
viru
also
mvanpvaccin
poni
show
sever
clinic
symptom
upon
influenza
viru
challeng
infect
suggest
induct
cellular
immun
respons
protect
capac
breathnach
et
al
zoonot
transmiss
pandem
potenti
variou
highli
pathogen
avian
influenza
virus
subtyp
develop
vaccin
human
consid
prioriti
sinc
de
jong
et
al
yang
et
al
vaccin
develop
complic
antigen
differ
clade
influenza
virus
within
subtyp
context
kreijtz
kreijtz
et
al
kreijtz
et
al
vaccin
either
recombin
mva
effici
induc
antibodi
respons
homolog
influenza
viru
moreov
immun
clade
abl
activ
antibodi
homolog
viru
also
clade
lesser
extent
clade
potent
activ
influenza
virusneutr
antibodi
correl
protect
efficaci
homolog
heterolog
challeng
infect
kreijtz
et
al
interestingli
except
immunogen
ha
antigen
influenza
confirm
anoth
studi
compar
recombin
mva
vaccin
express
ha
antigen
variou
influenza
virus
clade
hessel
et
al
also
prove
immunogen
protect
test
singleshot
vaccin
chicken
challeng
highli
pathogen
avian
influenza
viru
veit
et
al
cynomolgu
macaqu
primeboost
immun
abl
protect
anim
homolog
viru
infect
clade
influenza
viru
absenc
viru
infect
cell
lung
lack
fever
sever
interstiti
pneumonia
highlight
induct
solid
protect
immun
vaccin
anim
kreijtz
et
al
result
evalu
mice
also
demonstr
efficaci
vaccin
dosespar
singleshot
immun
minim
requir
induct
protect
homolog
heterolog
influenza
viru
challeng
infect
includ
singl
immun
pfu
plaqueform
unit
primeboost
immun
pfu
note
experi
protect
observ
absenc
detect
haspecif
antibodi
data
look
encourag
regard
pandem
risk
vaccin
protect
rapidli
minim
dose
kreijtz
et
al
context
recombin
mva
express
ha
pandem
turn
highli
immunogen
protect
test
mous
model
ferret
hessel
et
al
kreijtz
et
al
ferret
primeboost
vaccin
effici
activ
virusspecif
antibodi
reduc
clinic
sign
challeng
infect
anetherland
protect
sever
histopatholog
chang
lung
two
immun
also
significantli
lower
presenc
infecti
viru
upper
lower
respiratori
tract
kreijtz
et
al
due
promis
result
vivo
preclin
evalu
firstinman
phase
iiia
clinic
studi
facilit
vaccin
safe
toler
seriou
side
effect
observ
furthermor
candid
vaccin
prove
immunogen
individu
enrol
studi
effici
activ
antibodi
crossreact
homolog
heterolog
subtyp
influenza
virus
recent
emerg
highli
pathogen
avian
influenza
viru
subtyp
de
vri
et
al
note
primeboost
applic
via
intramuscular
rout
induc
level
influenza
antibodi
rais
expect
protect
capac
interestingli
booster
vaccin
allow
remark
enhanc
specif
antibodi
given
month
primari
immun
result
firstli
describ
major
benefit
booster
vaccin
recombin
mva
use
extend
time
period
primari
secondari
immun
futur
clinic
studi
use
similar
regimen
might
help
develop
new
vaccin
strategi
overal
induct
robust
level
influenza
haspecif
antibodi
expect
afford
crossprotect
immun
virus
influenza
viru
subtyp
addit
mvamedi
deliveri
codeliveri
influenza
viru
cell
antigen
consid
possibl
confer
broader
protect
variou
subtyp
review
see
altenburg
et
al
probabl
extens
test
cell
vaccin
recombin
mva
vaccin
express
influenza
viru
np
matrix
protein
lamb
et
al
candid
vaccin
also
shown
induc
influenzaspecif
cell
phase
iiia
clinic
studi
protect
human
experiment
influenza
challeng
infect
berthoud
et
al
lilli
et
al
final
aim
broadli
protect
univers
influenza
viru
vaccin
kamlangde
cowork
test
innov
recombin
mva
express
silico
gener
synthet
antigen
repres
mosaic
sequenc
virus
kamlangde
et
al
interestingli
candid
vaccin
protect
mice
virus
clade
also
infect
influenza
viru
taken
togeth
highli
encourag
data
support
clinic
evalu
exist
mva
candid
vaccin
develop
novel
recombin
mva
influenza
safe
effect
human
immunodefici
viru
hiv
vaccin
urgent
need
control
worldwid
hiv
epidem
howev
develop
vaccin
aid
repres
substanti
scientif
challeng
relat
hiv
antigen
variabl
lack
understand
immun
correl
protect
limit
avail
anim
model
enorm
constraint
associ
probabl
need
multipl
largescal
clinic
trial
differ
part
world
review
see
excler
et
al
moreov
fragil
immun
system
hivinfect
individu
set
high
standard
candid
vaccin
safeti
recent
past
highli
attenu
poxvirus
continu
play
major
role
intern
search
aid
vaccin
also
take
advantag
establish
technolog
vector
vaccin
product
industri
scale
differ
recombin
mvaexpress
hiv
protein
undergon
preclin
clinic
test
activ
protect
immun
respons
aid
often
combin
dnabas
andor
adenovir
vector
vaccin
review
see
iyer
amara
ondondo
recombin
mva
vaccin
target
differ
subtyp
continu
prove
safe
immunogen
addit
clinic
studi
goepfert
et
al
joachim
et
al
munseri
et
al
nilsson
et
al
import
new
find
includ
data
induct
high
level
antibodydepend
cellular
cytotoxicitymedi
antibodi
month
durabl
vaccineinduc
hiv
envspecif
antibodi
respons
context
necessari
target
antigen
compris
immunodefici
viru
envelop
env
protein
could
shown
elicit
antibodi
respons
enhanc
protect
capac
nonhuman
primat
chimer
simianhuman
immunodefici
viru
shiv
siv
challeng
infect
model
barouch
michael
barouch
picker
roeder
et
al
recent
approach
work
induct
broadli
neutral
antibodi
mucos
site
viral
entri
base
envspecif
vaccin
import
hiv
immunogen
deliv
mva
candid
vaccin
includ
gag
pol
nef
protein
target
induct
hivspecif
cell
addit
new
synthet
hivspecif
mosaic
immunogen
evalu
improv
antigen
induct
cell
ondondo
et
al
larg
number
differ
hiv
candid
vaccin
necessit
develop
preclin
model
system
evalu
select
promis
vaccin
candid
mani
preclin
experi
vari
degre
protect
homolog
immunodefici
viru
infect
found
predominantli
depend
challeng
viru
andor
anim
model
use
evalu
howev
hiv
extraordinari
genet
divers
holi
grail
aid
vaccin
would
crossprotect
differ
hiv
clade
major
scientif
challeng
find
appropri
antigen
epitop
elicit
crossprotect
immun
respons
sometim
induct
cellular
immun
primari
focu
hiv
vaccin
develop
gener
broadli
neutral
antibodi
also
believ
indispens
douek
et
al
previou
data
two
studi
macaqu
model
show
booster
vaccin
oligomer
nativ
env
protein
enhanc
envbind
virusneutr
antibodi
respons
prime
recombin
mva
vaccin
suggest
antibodi
inde
like
play
role
vaccineinduc
protect
earl
et
al
current
siv
shiv
challeng
infect
differ
nonhuman
primat
consid
appropri
anim
model
test
immunogen
efficaci
model
close
mimic
pathogenesi
hiv
infect
human
concern
viremia
progress
deplet
cell
clinic
manifest
aid
van
rompay
thorough
character
recombin
mva
candid
vaccin
siv
model
continu
elucid
protect
capac
siv
antigenspecif
immun
respons
chamcha
et
al
iyer
et
al
kwa
et
al
valentin
et
al
thu
nonhuman
primat
model
might
allow
gener
proofofconcept
data
antivir
immun
effect
inhibit
immunodefici
viru
replic
diseas
develop
addit
mva
vector
vaccin
proven
excel
candid
vaccin
develop
infecti
diseas
global
impact
tuberculosi
malaria
review
mcshane
william
incid
diseas
caus
mycobacterium
tuberculosi
steadili
increas
often
basi
povertyimpair
health
servic
widespread
hiv
infect
emerg
resist
tuberculosi
recent
effort
elicit
potent
antimycobacteri
immun
mva
vector
virus
serv
identifi
new
promis
target
antigen
result
develop
first
subunit
vaccin
enter
clinic
test
mcshane
et
al
sheehan
et
al
conserv
mycobacteri
antigen
turn
promis
immunogen
induct
antigenspecif
cell
tuberculosi
recombin
mva
candid
vaccineexpress
transcript
control
vacv
earlyl
promot
extens
test
preclin
model
phase
phase
iib
clinic
studi
vaccin
balbc
mice
induc
tcell
respons
confer
protect
challeng
tuberculosi
mcshane
et
al
importantli
approach
effici
trigger
activ
cellular
immun
respons
vaccin
recombin
success
evalu
boost
immunogen
effect
mycobacterium
bovi
bcg
primari
immun
preclin
studi
differ
anim
model
includ
mice
guinea
pig
nonhuman
primat
cattl
confirm
protect
efficaci
heterolog
bcg
boost
vaccin
experi
protect
associ
reduct
bacteri
load
lung
rather
steril
immun
goonetillek
et
al
william
et
al
b
unfortun
test
immun
larg
phase
iib
clinic
trial
children
africa
improv
compar
convent
bcg
immun
schedul
tameri
et
al
well
toler
immunogen
shown
induct
antigenspecif
cell
howev
immun
demonstr
signific
efficaci
tuberculosi
tuberculosi
infect
nevertheless
studi
provid
import
encourag
pool
safeti
data
recombin
mva
candid
vaccin
test
infant
overal
result
obtain
clinic
test
support
develop
improv
recombin
candid
vaccin
tuberculosi
also
includ
addit
antigen
tuberculosi
estim
death
million
clinic
ill
due
malaria
major
central
southern
africa
thu
effect
vaccin
malaria
urgent
requir
hoffman
et
al
varieti
antigen
plasmodium
falciparum
express
test
recombin
vacv
pathogenesi
malaria
involv
complex
life
cycl
includ
differ
blood
nonblood
life
stage
parasit
human
host
well
mosquito
host
major
challeng
choic
optim
target
antigen
mediat
protect
immun
respons
multipl
phase
malaria
desir
target
result
effici
activ
humor
immun
well
malariaspecif
cell
landmark
studi
schneider
cowork
evalu
recombin
mva
vaccin
mous
malaria
model
use
p
berghei
studi
demonstr
effici
induct
malariaspecif
cell
could
enhanc
use
dna
prime
combin
recombin
mva
boost
agent
note
studi
demonstr
need
antigenspecif
cell
induc
protect
p
berghei
sporozoit
challeng
infect
first
clinic
trial
initi
use
recombin
mva
express
import
malaria
liver
stage
antigen
trapcsp
alon
heterolog
primeboost
schedul
combin
adenovir
vector
gilbert
et
al
improv
antigen
achiev
fusion
trap
peptid
sequenc
encompass
plasmodiumspecif
multipl
epitop
metrap
gilbert
et
al
detail
moorthi
cowork
gener
singl
polypeptid
metrap
amino
acid
combin
multipl
epitop
string
consist
tcell
epitop
three
tcell
epitop
tetanu
toxin
bcg
pfcircumsporozoit
protein
pfcsp
two
bcell
epitop
within
establish
trap
antigen
dna
prime
recombin
mva
boost
schedul
evalu
safeti
immunogen
phase
iii
clinic
trial
human
sever
advers
effect
observ
applic
mvametrap
alon
combin
dna
prime
vaccin
moorthi
et
al
follow
clinic
evalu
immunogen
protect
assess
african
adult
malariaendem
area
heterolog
regimen
use
dna
prime
mva
boost
prove
immunogen
compar
homolog
applic
either
vaccin
use
alon
howev
despit
measur
immunogen
robust
protect
challeng
p
falciparum
could
detect
moorthi
et
al
moorthi
et
al
anoth
advanc
base
studi
test
differ
combin
primari
immun
recombin
fowlpox
recombin
mva
vaccin
next
step
includ
clinic
evalu
malaria
vaccin
candid
heterolog
primeboost
vaccin
booster
immun
result
effici
activ
malariaspecif
cell
adult
children
webster
et
al
howev
efficaci
test
field
studi
endem
area
fail
robustli
protect
malaria
infect
variou
stage
bejon
et
al
anoth
innov
approach
heterolog
primeboost
vaccin
conduct
rodriguez
colleagu
murin
p
berghei
infect
model
altern
usag
porcin
parvoviruslik
particl
deliv
cs
protein
peptid
sequenc
result
effici
prime
protect
tcell
respons
follow
booster
vaccin
recombin
mva
express
cs
antigen
recent
anoth
heterolog
primeboost
vaccin
schedul
thoroughli
evalu
use
chimpanzeeadenoviru
vector
prime
recombin
mva
booster
vaccin
review
see
sebastian
gilbert
combin
vector
immun
induc
high
frequenc
metrapspecif
tcell
respons
human
promis
approach
robustli
protect
p
falciparum
ewer
et
al
moreov
recent
studi
suggest
feasibl
develop
malaria
transmissionblock
vector
vaccin
target
p
falciparum
within
mosquito
antibodi
highlevel
transmissionblock
activ
could
elicit
upon
primeboost
immun
mice
recombin
chimpanze
adenoviru
mvaexpress
candid
malaria
antigen
kapulu
et
al
thu
futur
approach
develop
mva
vector
vaccin
malaria
aim
induct
balanc
immun
base
effici
humor
cellular
immun
respons
yet
complex
clinic
phase
iiiii
studi
human
endem
area
need
evalu
efficaci
new
promis
approach
newli
emerg
pathogen
repres
anoth
global
public
health
risk
suddenli
unexpectedli
aris
previous
unknown
ecolog
nich
case
anim
reservoir
thu
major
concern
zoonot
infect
transmit
anim
human
suffici
adapt
human
host
may
rapidli
spread
human
popul
kuiken
et
al
reusken
et
al
steffen
et
al
past
year
public
health
system
confront
multitud
new
pathogen
demonstr
differ
scenario
emerg
context
year
sudden
occurr
west
nile
fever
western
hemispher
new
york
citi
usa
often
mark
begin
new
era
epidem
review
see
suthar
et
al
wnv
member
genu
flavivirus
arboviru
continu
circul
differ
mosquito
speci
bird
major
anim
viru
reservoir
bite
infect
mosquito
wnv
transmit
mammalian
host
primarili
human
hors
caus
socal
west
nile
fever
sometim
result
neuroinvas
diseas
potenti
sever
outcom
especi
elderli
immunocompromis
human
viru
first
isol
febril
woman
west
nile
district
uganda
goldblum
et
al
sinc
observ
becom
endem
region
europ
africa
asia
period
caus
wnv
outbreak
human
andor
hors
viru
introduc
new
york
citi
district
queen
supposedli
infect
mosquito
bird
lanciotti
et
al
murray
et
al
nash
et
al
thu
wnv
reloc
new
popul
facilit
impress
spread
across
north
american
contin
lead
total
human
infect
death
http
wwwcdcgovwestnilestatsmap
concurr
viru
also
increasingli
emerg
european
countri
result
outbreak
sever
diseas
hors
human
thu
safe
effect
wnv
vaccin
human
urgent
need
particular
protect
atrisk
popul
recent
studi
test
differ
recombin
mva
vaccin
deliv
wnv
envelop
protein
wnve
fulfil
princip
requir
proceed
clinic
test
human
vaccin
immunogen
induct
neutral
antibodi
especif
tcell
respons
capac
protect
lethal
challeng
infect
evalu
differ
mous
model
mvawnv
candid
vaccin
allow
compar
perform
wnve
antigen
express
four
differ
conform
mvaprmm
wnve
produc
togeth
wnv
membran
protein
induc
synthesi
releas
viru
like
particl
vlp
upon
mva
infect
mvae
sol
produc
solubl
version
wnve
secret
infect
cell
mvae
tmv
mvae
tmc
promin
expos
wnve
antigen
cell
surfac
provid
heterolog
transmembran
domain
deriv
either
vacv
tmv
transmembran
domain
vaccinia
viru
chikungunya
viru
tmc
transmembran
domain
chikungunya
viru
upon
primeboost
vaccin
balbc
mice
four
mvawnv
candid
vaccin
elicit
circul
serum
antibodi
bind
recombin
wnve
protein
neutral
wnv
tissu
cultur
infect
addit
immun
class
iclass
iiknockout
mice
effici
induc
wnvespecif
tcell
respons
final
mvawnv
candid
vaccin
protect
mice
challeng
infect
lineag
lineag
wnv
activ
crossneutr
antibodi
thu
studi
warrant
evalu
recombin
mvawnv
vaccin
preclin
model
effort
select
develop
mvawnv
candid
vaccin
clinic
test
human
recent
famili
coronavirida
provid
differ
new
pathogen
suddenli
aris
ecolog
nich
sinc
two
novel
beta
coronavirus
introduc
human
popul
caus
acut
atyp
necrot
pneumonia
socal
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
earli
sar
epidem
initi
occur
southern
china
rapidli
spread
countri
caus
infect
death
bat
speci
civet
cat
identifi
anim
reservoir
transmit
viru
human
andor
anim
abrupt
emerg
sarscov
china
novemb
worldwid
distribut
end
repres
scenario
pandem
public
health
emerg
luckili
spread
diseas
could
prevent
infect
sarscov
detect
sinc
earli
success
contain
sar
like
due
multipl
caus
eg
rel
eas
clinic
case
isol
persist
pathogen
anim
reservoir
rare
enabl
transmiss
human
howev
lesson
learn
sar
includ
need
time
develop
specif
vaccin
counteract
outbreak
scenario
high
morbid
mortal
rate
lack
specif
treatment
option
effect
approach
deal
emerg
pathogen
vaccin
mva
excel
safeti
profil
wellestablish
vector
product
platform
hold
great
potenti
rapidli
develop
new
vaccin
emerg
pathogen
readi
use
immedi
public
health
respons
ideal
scenario
mva
emerg
vaccin
select
pathogen
risk
develop
undergo
preclin
phase
iii
clinic
evalu
alreadi
preepidem
time
case
diseas
outbreak
recombin
mva
candid
vaccin
could
immedi
test
efficaci
studi
use
vaccin
peopl
special
risk
endem
area
concept
alreadi
spur
develop
first
set
recombin
mva
candid
vaccin
highli
pathogen
avian
influenza
virus
recent
emerg
merscov
current
exampl
new
zoonot
agent
merscov
first
describ
septemb
contrast
experi
sar
epidem
merscov
continu
caus
diseas
human
fifth
year
first
appear
present
report
total
laboratori
confirm
case
includ
death
http
wwwwhointemergenciesmerscoven
epidemiolog
human
merscov
infect
center
middl
east
eg
qatar
saudi
arabia
jordan
unit
arab
emir
sporad
merscov
infect
also
spread
countri
europ
northamerica
asia
due
transmiss
travel
infect
middl
east
raj
cowork
identifi
human
cell
surfac
amino
peptidas
dipeptidyl
function
receptor
merscovmedi
entri
cell
raj
et
al
dromedari
camel
known
gener
accept
critic
anim
reservoir
respons
spread
viru
human
memish
et
al
meyer
et
al
raj
et
al
primari
zoonot
infect
result
interfamili
health
care
relat
secondari
transmiss
elderli
immunocompromis
person
among
peopl
risk
suffer
sever
lethal
merscov
infect
individu
risk
health
care
worker
peopl
close
contact
camel
group
consid
relev
target
popul
potenti
merscov
vaccin
far
licens
vaccin
merscov
sarscov
avail
differ
approach
undertaken
develop
effect
mean
prevent
cure
new
infecti
diseas
mva
test
viral
vector
vaccin
beta
coronavirus
envelop
spike
protein
proven
major
target
sarscovneutr
antibodi
et
al
sui
et
al
inde
recombin
mva
produc
sarscov
antigen
evalu
differ
anim
model
demonstr
induct
sarscovspecif
immun
respons
includ
sarscovneutr
antibodi
santigenspecif
cell
mice
rabbit
rhesu
macaqu
bisht
et
al
chen
et
al
prime
boost
immun
effect
inhibit
sarscov
replic
cynomolg
monkey
respiratori
sarscov
challeng
infect
suggest
induct
protect
immun
case
merscov
recombin
mva
express
protein
merscov
mvamerss
gener
rapidli
discoveri
mer
song
et
al
merscovsencod
sequenc
introduc
delet
site
iii
mva
genom
preclin
evalu
mvamerss
candid
vaccin
confirm
induct
merscovneutr
antibodi
merss
epitopespecif
cell
balbc
mice
compar
differ
dosag
applic
rout
volz
et
al
moreov
preclin
test
special
mous
model
allow
first
demonstr
protect
capac
mer
candid
vaccin
adenovirusmedi
transduct
human
dipeptidylpeptidas
receptor
balbc
mice
suscept
respiratori
merscov
challeng
infect
monitor
viru
load
allow
determin
efficaci
experiment
immun
zhao
et
al
viru
assum
persist
dromedari
camel
preclin
analysi
dromedari
camel
demonstr
immunogen
protect
efficaci
mvamerss
simultan
immun
intranas
intramuscular
rout
result
effici
induct
virusneutr
antibodi
serum
nasal
secret
vaccin
anim
contrari
mock
vaccin
control
anim
camel
vaccin
mvamerss
reveal
signific
reduct
excret
infecti
viru
viral
rna
transcript
merscov
challeng
infect
addit
vaccin
mvamerss
also
induc
activ
orthopoxvirusspecif
antibodi
readili
crossneutr
camelpox
viru
camelpox
viru
caus
sever
system
diseas
camel
case
fatal
rate
high
clinic
diseas
character
papul
pustul
initi
appear
primari
site
infect
follow
develop
gener
rash
fever
day
postinfect
young
camel
suscept
sever
clinic
diseas
activ
camelpox
virusneutr
antibodi
suggest
potenti
dual
use
candid
merscov
vaccin
dromedari
effici
protect
merscov
camelpox
viru
infect
data
support
gener
safeti
efficaci
mvamerss
candid
vaccin
introduc
possibl
applic
veterinari
vaccin
import
implic
one
health
concept
vaccin
dromedari
camel
area
endem
merscov
could
reduc
burden
viru
excret
anim
reservoir
thu
inhibit
transmiss
merscov
human
popul
addit
import
character
mvamerss
candid
vaccin
human
effort
ongo
start
firstinman
clinic
evalu
mvamerss
soon
possibl
first
clinic
phase
iii
test
safeti
immunogen
mvamerss
candid
vaccin
analyz
healthi
volunt
germani
result
phase
iii
clinic
evalu
prerequisit
test
vaccin
larger
phase
ii
studi
endem
countri
addit
avail
investig
drug
batch
mvamerss
might
allow
applic
emerg
vaccin
case
suddenli
occur
outbreak
scenario
viru
rapidli
transmit
spread
throughout
new
geograph
area
exemplari
introduct
merscov
south
korea
may
min
et
al
man
return
middl
east
diagnos
mer
day
initi
visit
hospit
medic
help
hospit
spread
merscov
occur
transmiss
sever
health
care
worker
patient
outbreak
total
individu
infect
total
death
context
govern
republ
korea
began
implement
intens
case
contact
manag
activ
end
stop
epidem
merscov
nonendem
region
howev
sudden
rapid
spread
merscov
south
korea
highlight
global
risk
newli
emerg
pathogen
might
unexpectedli
threaten
popul
jeongsun
et
al
kim
et
al
anoth
recent
exampl
sudden
reemerg
highli
infecti
pathogen
unpreced
ebola
viru
epidem
west
africa
start
continu
year
devast
widespread
ebola
viru
outbreak
viru
caus
diseas
case
death
mainli
geograph
link
africa
case
also
diagnos
travel
africa
unit
state
germani
franc
spain
great
britain
de
la
vega
et
al
quaglio
et
al
initi
larg
epidem
began
villag
meliand
gu
eck
edou
prefectur
guinea
end
like
bat
transmit
viru
human
follow
massiv
spread
diseas
villag
moreov
viru
caus
outbreak
identifi
notori
member
genu
ebolaviru
speci
zair
ebolaviru
ebov
baiz
et
al
consequ
epidem
west
africa
associ
high
morbid
mortal
rate
enabl
undamp
transmiss
perpetu
viru
popul
rather
long
time
period
gire
et
al
observ
ebolaviru
outbreak
past
far
effici
therapeut
avail
choi
croyl
also
vaccin
licens
protect
ebolaviru
howev
sinc
recent
epidem
research
activ
develop
evalu
candid
vaccin
ebolaviru
intensifi
promis
candid
alreadi
advanc
clinic
evalu
human
includ
recombin
vesicular
stomat
viru
vsv
deliv
ebolaviru
zair
glycoprotein
vsvebov
chimpanzeeadenoviru
zair
ebola
viru
zebov
also
express
ebolaviru
zair
glycoprotein
target
antigen
regard
strategi
use
heterolog
primeboost
immun
schedul
boost
appropri
recombin
mvaexpress
ebolaviru
zair
glycoprotein
ewer
et
al
tapia
et
al
strategi
support
data
preclin
evalu
candid
vaccin
nonhuman
primat
primeboost
vaccin
vaccin
alon
confer
protect
immun
period
sever
month
howev
robust
protect
lethal
challeng
ebov
could
obtain
follow
booster
vaccin
recombin
mvaebov
candid
vaccin
coexpress
ebolaviru
zair
sudan
glycoprotein
control
vaccinia
viru
earli
promot
stanley
et
al
approach
use
prime
mvaebov
boost
vaccin
develop
engin
multival
recombin
mva
coproduc
zebov
sudan
ebola
viru
glycoprotein
filoviru
antigen
mvabnfilo
first
phase
ib
clinic
studi
demonstr
safeti
toler
immunogen
prime
mvabnfilo
booster
immun
adult
unit
state
mali
without
observ
sever
side
effect
combin
mvabnfilo
vaccin
prove
highli
immunogen
shown
activ
ebovspecif
antibodi
tcell
respons
tapia
et
al
ewer
colleagu
investig
anoth
heterolog
primeboost
vaccin
schedul
healthi
adult
volunt
oxford
unit
kingdom
use
vector
vaccin
monoval
recombin
mva
encod
surfac
glycoprotein
zebov
immun
boost
mvaelicit
bcell
tcell
immun
respons
zebov
clearli
superior
induc
vector
vaccin
alon
ewer
et
al
nevertheless
heterolog
vaccin
strategi
two
differ
viral
vector
vaccin
complex
regimen
appli
larg
field
studi
case
emerg
vaccin
whole
popul
protect
rapidli
thu
interest
evalu
efficaci
primeboost
vaccin
scheme
base
mvaebov
summari
highli
versatil
safe
mva
vector
platform
particularli
use
effect
control
newli
emerg
reemerg
infecti
diseas
vector
system
may
readili
exploit
plugandplay
gener
approach
rapid
gener
vaccin
candid
suitabl
rapid
emerg
immun
simultan
clinicalstag
develop
new
licens
product
erad
human
smallpox
achiev
prophylact
use
vacv
immun
human
host
reservoir
caus
agent
varv
howev
member
genu
orthopoxviru
caus
zoonot
infect
kroon
et
al
mccollum
damon
vora
et
al
moreov
recent
fear
monkeypox
viru
mpxv
varv
could
use
biolog
weapon
renew
interest
safe
vaccin
varv
zoonot
orthopoxvirus
moss
mva
hold
great
promis
worldwid
use
thirdgener
smallpox
vaccin
due
wellestablish
characterist
concern
safeti
immunogen
jone
et
al
knitlova
et
al
meseda
et
al
tree
et
al
wyatt
et
al
mva
vaccin
licens
europ
activ
immun
smallpox
adult
use
situat
consid
necessari
protect
smallpox
accord
offici
recommend
european
medicin
agenc
data
multipl
phase
ii
clinic
studi
confirm
safeti
immunogen
mva
vaccin
patient
popul
consid
risk
convent
smallpox
vaccin
includ
individu
atop
dermat
hiv
infect
greenberg
et
al
overton
et
al
von
sonnenburg
et
al
addit
mva
success
test
cardiac
safeti
larg
phase
ii
clinic
trial
zitzmannroth
et
al
import
vaccin
base
replicationcompet
vacv
strain
associ
high
incid
myopericard
sever
cardiac
complic
addit
recent
data
clinic
studi
address
metaanalysi
mvainduc
immun
respons
variou
patient
popul
compar
evalu
inocul
rout
improv
formul
mva
vaccin
troy
et
al
today
erad
smallpox
lack
establish
human
diseas
repres
pathogenesi
system
orthopoxviru
infect
human
therefor
analyz
protect
efficaci
orthopoxvirusspecif
vaccin
straightforward
preclin
evalu
anim
model
requir
test
vaccinemedi
protect
relat
antigenspecif
respons
anim
model
must
mimic
target
poxviru
diseas
human
close
possibl
varv
infect
cynomolgu
macaqu
result
lethal
diseas
similar
smallpox
wahljensen
et
al
howev
varv
biosafeti
level
agent
handl
viru
highli
restrict
thu
sever
anim
model
use
orthopoxvirus
cowpox
viru
cpxv
mpxv
ectromelia
viru
ectv
vacv
develop
chapman
et
al
esteban
buller
mva
safe
smallpox
vaccin
test
differ
infect
model
mva
vaccin
intramuscular
subcutan
rout
protect
mice
sever
respiratori
challeng
infect
cpxv
vacvwr
coulibali
et
al
drexler
et
al
note
mva
could
also
protect
mice
lack
sever
compon
immun
system
resembl
highrisk
group
popul
would
requir
altern
standard
smallpox
vaccin
nonhuman
primat
challeng
infect
mpxv
appropri
model
evalu
preclin
efficaci
new
candid
smallpox
vaccin
standard
dosag
pfu
mva
robustli
protect
cynomolg
monkey
intraven
intratrach
mpxv
challeng
stittelaar
et
al
context
edghillsmith
cowork
demonstr
essenti
need
antibodi
protect
fatal
monkeypox
diseas
edghillsmith
et
al
one
major
limit
orthopoxviru
infect
model
use
vacv
mpxv
cpxv
test
protect
capac
vaccin
high
amount
infecti
viru
pfu
requir
induc
lethal
diseas
contrast
infecti
particl
varv
could
gener
fatal
smallpox
diseas
naiv
human
overcom
shortcom
ectv
infect
mice
serv
addit
highli
appropri
model
reassess
correl
protect
immun
review
sigal
ectv
caus
agent
mousepox
natur
mous
pathogen
caus
classic
system
poxviru
diseas
esteban
buller
low
amount
ectv
suffici
infect
induct
lethal
mousepox
diseas
suscept
mous
strain
asymptomat
incub
period
day
follow
intranas
infect
mousepox
diseas
start
respiratori
tract
follow
system
viru
spread
intern
organ
liver
spleen
paran
et
al
parker
et
al
specif
sign
ill
character
sever
bronchopneumonia
hepat
mice
surviv
system
phase
sever
diseas
develop
characterist
pustular
rash
skin
reminisc
seen
human
smallpox
ectvmous
model
offer
opportun
studi
orthopoxviru
pathogen
experiment
easili
access
natur
host
ectv
highli
adapt
mous
immun
system
allow
thoroughli
analyz
mechan
viral
immun
evas
vaccineinduc
immun
protect
sever
studi
evalu
mva
vaccinemedi
protect
lethal
mousepox
diseas
detail
coulibali
cowork
demonstr
use
respiratori
ectv
challeng
infect
improv
model
system
efficaci
test
intramuscular
immun
singl
dose
pfu
mva
prevent
sever
diseas
death
mice
challeng
week
vaccin
singl
dose
robustli
protect
sign
ill
diseas
respiratori
mousepox
challeng
howev
vaccin
pfu
vacv
wyeth
mice
suffer
sever
lethal
diseas
coulibali
et
al
cpxv
challeng
model
differ
candid
vaccin
equal
protect
underlin
impact
choos
specif
challeng
viru
studi
demonstr
need
data
variou
preclin
model
key
compon
develop
nextgener
orthopoxvirusspecif
vaccin
applic
human
case
emerg
newli
aris
highli
pathogen
orthopoxvirus
eg
unintent
intent
releas
varv
vaccin
protocol
rapid
induct
protect
immun
urgent
need
reardon
sass
gelderblom
smallpox
vaccin
histor
report
vacv
applic
time
window
day
exposur
varv
may
protect
analysi
mva
emerg
vaccin
confirm
shortterm
protect
capac
vaccin
mice
latest
appli
day
lethal
respiratori
challeng
vacv
strain
wr
postexposur
prophylaxi
could
achiev
vacvwr
model
independ
dosag
applic
rout
staib
et
al
howev
test
emerg
vaccin
ectvmous
model
standard
dosag
pfu
mva
robustli
protect
lethal
respiratori
mousepox
infect
day
challeng
even
natur
virushost
system
pfu
mva
also
prevent
death
sever
diseas
appli
day
lethal
challeng
howev
postexposur
vaccin
could
inhibit
onset
sign
diseas
includ
respiratori
symptom
bodi
weight
loss
paran
et
al
followup
studi
kremer
colleagu
analyz
immun
compon
mediat
rapid
protect
detail
kremer
et
al
analysi
mvainduc
protect
mice
defin
defici
innat
adapt
immun
identifi
cell
essenti
requir
allow
mvainduc
tcell
expans
interestingli
select
compon
innat
immun
system
b
cellmedi
respons
fulli
dispens
prevent
fatal
diseas
immun
given
day
challeng
analyz
protect
capac
mva
immun
mice
lack
cell
b
cell
mice
could
protect
lethal
ectv
challeng
infect
result
underlin
prerequisit
adapt
cellular
immun
mediat
rapid
protect
perforinmedi
cytotox
proven
key
immun
mechan
case
emerg
rapid
induct
protect
immun
vaccin
desir
prevent
morbid
mortal
instant
activ
protect
virusspecif
immun
singleshot
vaccin
would
ideal
moreov
possibl
dosespar
immun
regimen
would
increas
number
peopl
vaccin
volz
cowork
assess
minim
requir
induct
protect
immun
lethal
ectv
challeng
infect
day
immun
mva
mice
intramuscularli
vaccin
tenfold
increas
dose
mva
start
pfu
mva
standard
dosag
interestingli
minim
amount
pfu
fulli
protect
mice
lethal
respiratori
challeng
infect
ectv
moreov
inocul
pfu
mva
still
suffici
prevent
death
vaccin
anim
could
protect
induct
mousepox
diseas
analysi
immun
respons
identifi
cell
key
compon
mediat
rapid
protect
low
dose
immun
model
moreov
mva
immun
low
dosag
also
protect
mice
indic
effici
activ
cellular
immun
even
absenc
type
ifn
signal
monitor
virusspecif
tcell
respons
mice
vaccin
minim
protect
dose
mva
found
significantli
enhanc
level
antigenspecif
cell
anim
mva
vaccin
ectv
challeng
compar
mice
vaccin
initi
prime
cell
mva
immun
appear
highli
effici
even
low
dose
mediat
rapid
vivo
burst
pathogenspecif
cell
upon
challeng
find
defin
strike
requir
protect
emerg
immun
sever
system
infect
orthopoxvirus
data
import
practic
relev
public
health
produc
suffici
amount
vaccin
expect
major
challeng
outbreak
occur
moreov
prevent
infect
may
requir
similar
immun
mechan
elicit
rapid
protect
immun
henc
mva
could
extrem
use
vaccin
deliv
heterolog
cell
antigen
particularli
infecti
diseas
fit
scenario
emerg
vaccin
thu
studi
evalu
recombin
mva
candid
vaccin
emerg
vaccin
might
promis
develop
new
prophylact
therapeut
approach
today
almost
year
first
licens
germani
mva
well
establish
safetytest
immunogen
efficaci
thirdgener
smallpox
vaccin
european
medicin
agenc
canada
health
grant
market
author
mva
vaccin
immun
varv
infect
absenc
human
smallpox
natur
occur
varv
european
medicin
agenc
thu
efficaci
data
need
gener
anim
model
orthopoxviru
infect
consid
repres
human
smallpox
similar
licens
process
us
food
drug
administr
ongo
appear
advanc
stage
despit
erad
varv
three
decad
ago
effort
still
import
mostli
due
threat
varv
beingaccid
intentionallyreleas
unprotect
human
popul
moreov
use
licens
mva
vaccin
ideal
protect
individu
riskinclud
laboratori
workersagainst
zoonot
orthopoxvirus
cpxv
mpxv
continu
cycl
rodent
reservoir
caus
diseas
human
addit
year
mva
continu
improv
extrem
safe
effici
viral
vector
system
synthesi
high
level
foreign
protein
nonpermiss
human
cell
moment
recombin
mva
virus
express
variou
heterolog
antigen
among
promis
vector
candid
develop
innov
vaccin
strategi
protect
complex
infect
aid
tuberculosi
malaria
rare
threaten
emerg
diseas
desir
common
characterist
mva
viral
vector
vaccin
includ
genet
stabil
wellestablish
product
procedur
gener
safeti
environ
result
come
clinic
test
variou
recombin
mva
vaccin
emphas
excel
safeti
record
immunogen
vaccin
human
context
recent
clinic
find
noteworthi
repeat
vaccin
recombin
mva
result
substanti
booster
induct
antigenspecif
antibodi
even
presenc
high
level
mvaspecif
immun
result
togeth
promis
data
gain
combin
applic
mva
variou
viral
vector
platform
greatli
enhanc
gener
accept
viral
vector
nextgener
candid
vaccin
addit
promis
characterist
concern
immunogen
nonrepl
recombin
mva
vaccin
also
well
posit
satisfi
stringent
requir
broad
safeti
variou
set
mva
vaccin
appear
highli
suitabl
use
immunocompromis
individu
elderli
repres
import
target
popul
everag
popul
industri
world
time
recombin
mva
also
safe
immun
person
sever
comorbid
eg
hiv
infect
tuberculosi
malaria
often
seen
develop
nation
new
vaccin
rapidli
protect
threaten
emerg
pathogen
urgent
need
highlight
wholist
top
want
emerg
diseas
like
caus
major
epidem
longstand
experi
mva
vector
vaccin
platform
preclin
clinic
research
lead
import
contribut
develop
protect
vaccin
strategi
newli
emerg
pathogen
final
excit
result
ongo
fundament
research
biolog
mva
spur
possibl
even
improv
efficaci
futur
mva
vaccin
exemplari
area
research
target
still
unknown
function
hostregulatori
gene
remain
conserv
mva
genom
inde
modul
function
activ
regulatori
mva
protein
could
benefici
enhanc
immunogen
mva
vaccin
activ
innat
andor
adapt
immun
respons
heterolog
antigen
